Characterization of focal hepatic lesions with ferucarbotran (Resovist)-enhanced T2 and T2＊-weighted MR imaging

The purpose of this study was to characterize focal hepatic lesions through pre and post ferucarbotran-enhanced T2 and T2＊-weighted imaging and to help differentiate benign and malignant lesions 대상 및 방법： Consecutive 34 patients with 52 hepatic lesions underwent MRI before and after intravenous bolus injection of ferucarbotran (Resovist Sobering, Berlin, Germany) for evaluation of focal hepatic lesions. Lesions included hemangiomas (n=17), metastases (n=12), cysts (n=10), hepatocellular carcinomas (n=8), dysplastic nodules (n=4), and focal fat deposit (n=1). T2-weighted fast spin echo (TR/TE： 4060/138) and gradient echo T2＊-weighted images(TR/TE： 140/5.3, FA = 90) were obtained according to the institutional routine imaging protocol. Lesional signal-intensity and lesion-to-liver contrast changes were measured by contrast-to-noise ratio (CNR) from region of interest.